DNAtrix signs agreement to utilize Alcyone's MEMS platform for direct drug delivery into glioblastoma

Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM).

"We are excited to have the opportunity to explore the use of Alcyone's MEMS platform for direct drug delivery into glioblastoma. Our micron sized microelectromechanical system (MEMS) based multi-channeled tip and other proprietary features are specifically designed to address the key challenges of optimized and targeted bio-distribution, in addition to avoiding the blood brain barrier for novel biologics such as those pioneered by DNAtrix," commented PJ Anand, Alcyone's founder and chief executive officer.

Dr. E. Antonio Chiocca, MD., PhD., chairman of neurosurgery at Brigham and Women's Hospital and professor of neurosurgery at Harvard Medical School and also is a scientific advisor for both companies commented, "Reducing the risk of sub-optimal delivery in the brain is critical to therapeutic success. This partnership between Alcyone and DNAtrix increases the chance for even greater efficacy with this product candidate.""We are pleased to have the use of this best-in-class brain delivery platform for treating brain cancer," said Frank Tufaro, Ph.D., chief executive officer of DNAtrix. "Circumventing the blood brain barrier addresses an industry-wide challenge and should make it much easier for the physician to deliver a more effective therapeutic dose of DNX-2401 to the tumor."

Source: Alcyone Lifesciences, Inc.; DNAtrix, Inc.

 

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.